High incidence of septic shock caused by Streptococcus pneumoniae serotype 3 - a retrospective epidemiological study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Ahl, Jonas ^a,b   Littorin, Nils ^a   Forsgren, Arne ^a   Odenholt, Inga ^b   Resman, Fredrik ^a,b   Riesbeck, Kristian ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Invasive pneumococcal disease; Sepsis; Serotype 19F; Serotype 3; Streptococcus pneumoniae

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PNEUMOCOCCAL INFECTION; RETROSPECTIVE STUDY; SEPTIC SHOCK; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SWEDEN; CLASSIFICATION; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RISK FACTOR; SEROTYPING; SHOCK, SEPTIC; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTYPING; SHOCK, SEPTIC; STREPTOCOCCUS PNEUMONIAE; SWEDEN; YOUNG ADULT;

EID: 84886878416     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-492     Document Type: Article

References (26)

1. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374(9700):1543-1556. 10.1016/S0140-6736(09)61114-4, 19880020.
2. Weiser JN. The pneumococcus: why a commensal misbehaves. J Mol Med (Berl) 2009, 88(2):97-102.
3. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004, 190(7):1203-1211. 10.1086/423820, 15346329.
4. Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009, 49(2):e23-e29. 10.1086/600045, 19522653.
5. Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon S, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42(4):451-459. 10.1086/499242, 16421787.
6. Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, et al. Association of serotypes of streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007, 45(1):46-51. 10.1086/518538, 17554699.
7. Berg S, Trollfors B, Persson E, Backhaus E, Larsson P, Ek E, et al. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006, 38(6-7):427-432.
8. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6(5):e1000081. 10.1371/journal.pmed.1000081, 2680036, 19468297.
9. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from invasive streptococcus pneumoniae disease revisited. BMC Infect Dis 2004, 4:21. 10.1186/1471-2334-4-21, 455681, 15228629.
10. Ruckinger S, von Kries R, Siedler A, van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 2009, 28(2):118-122. 10.1097/INF.0b013e318187e215, 19116604.
11. Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Ruckinger S, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010, 51(6):692-699. 10.1086/655828, 2927802, 20715907.
12. Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Linares J, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax Jan 2010, 65(1):77-81.
13. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 1992, 60(1):111-116. 257510, 1729176.
14. Kahlmeter G. The Swedish refence group for antibiotics (SRGA) and its subcommittee on methodology (SRGA-M) 2011, The Swedish refence group for Antibiotics (SRGA) and its subcommittee on methodology (SRGA-M), [updated 2011-02-21]; Available from: http://www.srga.org.
15. Claesson BHH, Nyberg A, Thore M, Wollin R, Akerlind B. Referensmetodik för laboratoriediagnostik vid kliniska mikrobiologiska laboratorier 2005, Swedish Institute for Infectious Disease Control, [cited 2011 2011-01-01]; Available from: http://www.referensmetodik.smi.se/w/Huvudsida.
16. Halbert SP, Swick L, Sonn C. The use of precipitin analysis in agar for the study of human streptococcal infections: II ouchterlony and oakley technics. J Exp Med 1955, 101(5):557-576. 10.1084/jem.101.5.557, 2136456, 14367679.
17. Lund EHJ. Laboratory diagnosis, serology and epidemiology of streptococcus pneumoniae 1978, New York: Academic Press.
18. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976, 43(6):699-709.
19. Inghammar M, Engstrom G, Lofdahl CG, Egesten A. Validation of a COPD diagnosis from the Swedish inpatient registry. Scand J Public Health Dec 2012, 40(8):773-776.
20. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36(1):296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
21. Furebring MBM, Cronqvist J, Follin P, Gille-Johnsson P, Gårdlund B, Lanbeck P, Ljungström L, Otto G, Sjölin J, Svefors J, Vikerfors J. Vårdprogram svår sepsis och septisk chock - tidig identifiering och initial handläggning 2008, [cited 2011 2011-01-01]; Available from: http://www.infektion.net/klinik/Sepsis/Vardprogram_Sepsis.pdf.
22. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002, 35(5):547-555. 10.1086/341896, 12173128.
23. Wood WB, Smith MR. The inhibition of surface phagocytosis by the capsular slime layer of pneumococcus type III. J Exp Med 1949, 90(1):85-96. 10.1084/jem.90.1.85, 2135934, 18152341.
24. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011, 10(3):307-322. 10.1586/erv.11.8, 21434799.
25. Dagan RPS, Juergens C, Greenberg D, Givon-Lavi N, Gurtman A, Kohberger K, Gruber WC, Scott DA. The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) additional serotypes on nasopharyngeal colonization 2012, Foz do Iguaçu, Brazil: Iguaçu Falls, Brazil, A randomized double-blind pediatric trial the 8th international symposium of pneumococci and pneumococcal disease, p. Abstract 312.
26. Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 2012, 12:207. 10.1186/1471-2334-12-207, 3462147, 22954038.